Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 RCT of BMS-986165 (deucravacitinib) in moderate to severe ulcerative colitis
jRCT2080224801Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2019
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Deucravacitinib 6 mg BID with Placebo (2 arms). Primary endpoint: Clinical remission at Week 12 (modified Mayo score). Started Jul 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080224801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224801.